La farmaco-resistenza di Mycobacterium tuberculosis nei pazienti con infezione da HIV e tubercolosi polmonare in Roma: 1987-1996

Translated title of the contribution: Drug-resitant pulmonary tuberculosis in HIV infected patients in Rome: 1987-1996

F. Palmieri, A. M. Pellicelli, E. Girardi, A. Rianda, E. Bordi, A. Festa, S. Catania, C. D'Amato

Research output: Contribution to journalArticle

Abstract

A retrospective chart review was performed on 118 HIV infected patients with pulmonary tuberculosis hospitalized between 1987 and 1996 in a tertiary care center for Infectious Diseases in Rome. The aims of this study were: a) to evaluate global prevalence of and risk factors for drug-resistant Mycobacterium tuberculosis and multidrug resistant tuberculosis; b) to assess trends in prevalence of drug-resistant tuberculosis over the 10-year study period. Prevalence of drug resistance of first Mycobacterium tuberculosis isolates was tested on Lowenstein-Jensen medium with the proportional method. Of the 118 patients studied, 83 had never been treated for tuberculosis and 35 had already been treated for at least 1 month. The overall prevalence of resistance to one or more drugs was 25% (17% in never treated patients vs 46% in already treated patients; p = 0.002). Five percent of isolates were resistant to both isoniazid and rifampin (1% in never treated patients vs 14% in already treated patients; p = 0.008). Resistance rates to individual drugs were: isoniazid 14%, rifampin 8%, ethambutol 0%, streptomycin 13%. During the study period no significant variations in prevalence of drug-resistant tuberculosis were found. In our area, empiric therapy should include 4 drugs: as well as isoniazid, rifampin and pyrazinamide, we recommend ethambutol. Surveillance of drug-resistant tuberculosis is needed. Directly observed therapy should be considered for HIV patients in order to prevent increases in drug resistance, relapses, and treatment failures.

Original languageItalian
Pages (from-to)139-145
Number of pages7
JournalAnnali Italiani di Medicina Interna
Volume13
Issue number3
Publication statusPublished - 1998

Fingerprint

Pulmonary Tuberculosis
Multidrug-Resistant Tuberculosis
HIV
Pharmaceutical Preparations
Isoniazid
Rifampin
Ethambutol
Mycobacterium tuberculosis
Drug Resistance
Directly Observed Therapy
Pyrazinamide
Streptomycin
Treatment Failure
Tertiary Care Centers
Communicable Diseases
Tuberculosis
Recurrence

ASJC Scopus subject areas

  • Internal Medicine

Cite this

La farmaco-resistenza di Mycobacterium tuberculosis nei pazienti con infezione da HIV e tubercolosi polmonare in Roma : 1987-1996. / Palmieri, F.; Pellicelli, A. M.; Girardi, E.; Rianda, A.; Bordi, E.; Festa, A.; Catania, S.; D'Amato, C.

In: Annali Italiani di Medicina Interna, Vol. 13, No. 3, 1998, p. 139-145.

Research output: Contribution to journalArticle

@article{b09a40ed72014c6ba9aa0ec1cfc66efc,
title = "La farmaco-resistenza di Mycobacterium tuberculosis nei pazienti con infezione da HIV e tubercolosi polmonare in Roma: 1987-1996",
abstract = "A retrospective chart review was performed on 118 HIV infected patients with pulmonary tuberculosis hospitalized between 1987 and 1996 in a tertiary care center for Infectious Diseases in Rome. The aims of this study were: a) to evaluate global prevalence of and risk factors for drug-resistant Mycobacterium tuberculosis and multidrug resistant tuberculosis; b) to assess trends in prevalence of drug-resistant tuberculosis over the 10-year study period. Prevalence of drug resistance of first Mycobacterium tuberculosis isolates was tested on Lowenstein-Jensen medium with the proportional method. Of the 118 patients studied, 83 had never been treated for tuberculosis and 35 had already been treated for at least 1 month. The overall prevalence of resistance to one or more drugs was 25{\%} (17{\%} in never treated patients vs 46{\%} in already treated patients; p = 0.002). Five percent of isolates were resistant to both isoniazid and rifampin (1{\%} in never treated patients vs 14{\%} in already treated patients; p = 0.008). Resistance rates to individual drugs were: isoniazid 14{\%}, rifampin 8{\%}, ethambutol 0{\%}, streptomycin 13{\%}. During the study period no significant variations in prevalence of drug-resistant tuberculosis were found. In our area, empiric therapy should include 4 drugs: as well as isoniazid, rifampin and pyrazinamide, we recommend ethambutol. Surveillance of drug-resistant tuberculosis is needed. Directly observed therapy should be considered for HIV patients in order to prevent increases in drug resistance, relapses, and treatment failures.",
author = "F. Palmieri and Pellicelli, {A. M.} and E. Girardi and A. Rianda and E. Bordi and A. Festa and S. Catania and C. D'Amato",
year = "1998",
language = "Italian",
volume = "13",
pages = "139--145",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "3",

}

TY - JOUR

T1 - La farmaco-resistenza di Mycobacterium tuberculosis nei pazienti con infezione da HIV e tubercolosi polmonare in Roma

T2 - 1987-1996

AU - Palmieri, F.

AU - Pellicelli, A. M.

AU - Girardi, E.

AU - Rianda, A.

AU - Bordi, E.

AU - Festa, A.

AU - Catania, S.

AU - D'Amato, C.

PY - 1998

Y1 - 1998

N2 - A retrospective chart review was performed on 118 HIV infected patients with pulmonary tuberculosis hospitalized between 1987 and 1996 in a tertiary care center for Infectious Diseases in Rome. The aims of this study were: a) to evaluate global prevalence of and risk factors for drug-resistant Mycobacterium tuberculosis and multidrug resistant tuberculosis; b) to assess trends in prevalence of drug-resistant tuberculosis over the 10-year study period. Prevalence of drug resistance of first Mycobacterium tuberculosis isolates was tested on Lowenstein-Jensen medium with the proportional method. Of the 118 patients studied, 83 had never been treated for tuberculosis and 35 had already been treated for at least 1 month. The overall prevalence of resistance to one or more drugs was 25% (17% in never treated patients vs 46% in already treated patients; p = 0.002). Five percent of isolates were resistant to both isoniazid and rifampin (1% in never treated patients vs 14% in already treated patients; p = 0.008). Resistance rates to individual drugs were: isoniazid 14%, rifampin 8%, ethambutol 0%, streptomycin 13%. During the study period no significant variations in prevalence of drug-resistant tuberculosis were found. In our area, empiric therapy should include 4 drugs: as well as isoniazid, rifampin and pyrazinamide, we recommend ethambutol. Surveillance of drug-resistant tuberculosis is needed. Directly observed therapy should be considered for HIV patients in order to prevent increases in drug resistance, relapses, and treatment failures.

AB - A retrospective chart review was performed on 118 HIV infected patients with pulmonary tuberculosis hospitalized between 1987 and 1996 in a tertiary care center for Infectious Diseases in Rome. The aims of this study were: a) to evaluate global prevalence of and risk factors for drug-resistant Mycobacterium tuberculosis and multidrug resistant tuberculosis; b) to assess trends in prevalence of drug-resistant tuberculosis over the 10-year study period. Prevalence of drug resistance of first Mycobacterium tuberculosis isolates was tested on Lowenstein-Jensen medium with the proportional method. Of the 118 patients studied, 83 had never been treated for tuberculosis and 35 had already been treated for at least 1 month. The overall prevalence of resistance to one or more drugs was 25% (17% in never treated patients vs 46% in already treated patients; p = 0.002). Five percent of isolates were resistant to both isoniazid and rifampin (1% in never treated patients vs 14% in already treated patients; p = 0.008). Resistance rates to individual drugs were: isoniazid 14%, rifampin 8%, ethambutol 0%, streptomycin 13%. During the study period no significant variations in prevalence of drug-resistant tuberculosis were found. In our area, empiric therapy should include 4 drugs: as well as isoniazid, rifampin and pyrazinamide, we recommend ethambutol. Surveillance of drug-resistant tuberculosis is needed. Directly observed therapy should be considered for HIV patients in order to prevent increases in drug resistance, relapses, and treatment failures.

UR - http://www.scopus.com/inward/record.url?scp=0031723248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031723248&partnerID=8YFLogxK

M3 - Articolo

C2 - 9859569

AN - SCOPUS:0031723248

VL - 13

SP - 139

EP - 145

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 3

ER -